L-Nutra Attracts $36.5 Million Investment to Boost Medical Nutrition Innovations

L-Nutra, a pioneering company in nutri-technology, has announced a significant achievement in its funding efforts. The firm recently secured a $36.5 million investment from Mubadala Investment Company. This funding round, part of L-Nutra's Series D, now totals $83.5 million, reflecting the increasing interest and confidence in science-driven nutrition aimed at promoting longevity and treating chronic diseases.

Mubadala, a reputable sovereign investor from Abu Dhabi with over $330 billion in assets, seeks to support L-Nutra's mission to enhance healthcare through innovative nutrition solutions. This partnership will not only further L-Nutra’s research and development but also facilitate the establishment of a new joint venture in Abu Dhabi. This venture is set to provide cutting-edge medical nutrition therapies and individualized dietary solutions specifically designed for healthy aging and managing diseases for the Middle East and North Africa (MENA) region.

Joseph Antoun, MD, PhD, the Chairman and CEO of L-Nutra, commented on the partnership, stating, "We are on the cusp of enhancing human healthspan, adding years to our life and life to our years. By reformulating food into clinically validated nutrition programs, we can support those wanting to embark on a healthy longevity journey."

The collaboration between L-Nutra and Mubadala is expected to lead to numerous benefits for local populations. Already, the two organizations have begun implementing nutrition and education initiatives in seven schools across Abu Dhabi. These programs aim to promote healthier lifestyle choices among students, highlighting the need for nutrition education as a crucial part of overall health management.

Ismail Ali Abdulla, Executive Director of UAE Clusters at Mubadala, elaborated on Abu Dhabi's ambitions, emphasizing that this investment will help position the region as a leading hub for longevity science and preventive health. This aligns with Mubadala's broader strategy focused on investing in solutions that enhance human health and well-being while contributing to the economic diversification of the UAE.

L-Nutra's investment from Mubadala complements the support from other impressive investors like Brentwood Associates and Stéphane Bancel, who has played a vital role in the vaccination efforts against COVID-19 through his work at Moderna. This diverse pool of funding will surely aid L-Nutra in pushing the envelope on nutritional science and its applications in healthcare.

L-Nutra has been at the forefront of developing groundbreaking nutrition formulations guided by cellular longevity science, working with 18 global research centers. The company prides itself on its extensive portfolio of clinical studies, a robust patent presence, and a growing number of products designed to improve health outcomes through nutrition. Notable programs such as Prolon offer personalized solutions for longevity and the management of chronic diseases—offering a glimpse into a future where nutrition is a cornerstone in the medical treatment landscape.

With this recent influx of capital and the strategic partnership with Mubadala, L-Nutra is positioned to expand its innovative nutritional therapies on a global scale, significantly contributing to the field of longevity science and medical nutrition. As they move forward, the company's commitment to leveraging nutrition as medicine will likely redefine healthcare norms and create new paradigms in health management.

For more information about L-Nutra and its various initiatives, visit www.l-nutra.com.

For more on Mubadala, please check www.mubadala.com.